All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

Martin DreylingExecutive Steering Committee Member

Professor Martin Dreyling is Professor of Medicine and Head of the lymphoma program in Medical Clinic III, Groβhadern ClinicLudwig-Maximilians-Universität, Munich, DE. He studied at the universities of DüsseldorfGiessenTübingen, and Würzburg, DE, and completed his clinical training at the universities of BonnMünsterGöttingen, and Munich, DE. In addition, he was Visiting Scientist at the University of Chicago, US, between 1992−1995.

His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation, and secondary genetic alterations, as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including novel antibodies and molecular targeted approaches, like inhibitors of the B-cell receptor pathway.

Prof. Dreyling is Coordinator of the European MCL Network and Assistant Coordinator of the German Low-Grade Lymphoma Study Group. He has co-authored numerous scientific papers, book chapters, and abstracts in international peer-reviewed journals.

Positions of responsibility/awards:

  • Coordinator of the European MCL Network since 2003
  • On the advisory board for the German Society for Hematology and Medical Oncology (DGHO) from 2004–2017
  • On the board of the German Study Group for Low-grade Malignant Lymphomas (GLSG) since 2002
  • Coordinator of the Center for Malignant Hematology (HaemaKUM) since 2012
  • Received the Ellen Glesby Leadership Award, 2007
  • Received the Fritz Acker prize, 2015
  • Received the Hermansky Award for Hematology Oncology, 2017
||